Combination PARP and HDAC inhibition as a therapeutic strategy targeting liver cancer stem cells?

Catherine E. Willoughby, Helen L. Reeves


Advances in imaging, surgery and medical therapy over the last few decades have resulted in steadily-declining cancer mortality rates across the globe. Mortality attributed to primary liver cancer, however, continues to rise (1). Liver cancer is responsible for over 700,000 deaths per year and is the second highest cause of cancer-related deaths worldwide (2).